 |
        |
Alan Levy, Ph.D.Independent Board Member Dr. Levy joined the ORTHOCON® Board of Directors in 2006. He currently is a Venture Partner to the medical device investment team at Frazier Healthcare Ventures. Dr. Levy has over 30 years of senior operational experience in the medical device industry. Most recently, he was the President and CEO of Northstar Neuroscience, a company developing innovative therapies for neurological diseases and disorders. Dr. Levy previously served as President and CEO of Heartstream, a company that developed, manufactured, and marketed an innovative automatic external defibrillator (AED) that revolutionized the treatment of sudden cardiac arrest. He successfully guided the company through product development, several rounds of venture financing, FDA clearance and product launch, manufacturing scale-up, an IPO, worldwide sales and distribution, and ultimately orchestrated the sale of the company to Hewlett-Packard. Prior to joining Heartstream, he was President of Heart Technology, a company that developed, manufactured, and marketed devices for removing plaque from coronary arteries. Dr. Levy effectively led Heart Technology through key business and product development milestones including FDA clearance, manufacturing scale-up, an IPO, and worldwide sales and distribution. The company was sold to Boston Scientific in 1995. Before joining Heart Technology, Dr. Levy was Vice President of Research and New Business Development and a member of the Board of the Ethicon division of Johnson & Johnson. At Ethicon, he was responsible for the acquisition and/or development of a large number of medical products, including synthetic absorbable sutures, coronary stents, surgical staplers and other mechanical wound closure products, growth factors for accelerated wound healing, and devices for minimally invasive surgery. Dr. Levy is a member of the Board of Trustees of Seattle Biomedical Research Institute, a not-for-profit institute conducting research on infectious diseases such as AIDS, malaria and pneumonia. He received his B.S. in chemistry from City University of New York and his Ph.D. in organic chemistry from Purdue University. Return to Leadership |
 |
||||||
 |
 |
ORTHOCON® estimates that over 3.5 million patients undergoing surgeries in the United States and Europe each year could benefit from the intraoperative use of HEMASORB.
 |
|
ORTHOCON® Names David J. Hart Vice President of Business Operations
March 15, 2012 - Click to Download Canaan Partners Closes $600 Million Fund, Canaan IX January 9, 2012 - Click to Read More |
||
|
||||||
